Stocktoria
Milestone Pharmaceuticals Inc. MIST
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-09
Milestone Pharmaceuticals Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $18.1M | $14.4M | $31.1M | $39.8M | $38.7M |
| Operating income | -$62.1M | -$42.1M | -$61.1M | -$59.6M | -$43.1M |
| Interest expense | — | — | $2.6M | — | — |
| Net income | -$63.1M | -$41.5M | -$59.7M | -$58.4M | -$42.9M |
| EPS (diluted) | $-0.75 | $-0.67 | $-1.39 | $-1.38 | $-1.02 |
| Operating cash flow | -$49.0M | -$28.8M | -$46.4M | -$52.5M | -$33.2M |
| Free cash flow | -$49.3M | -$28.9M | -$46.5M | -$52.7M | — |
| Cash & equivalents | $73.0M | $25.3M | $13.8M | $7.6M | $114.1M |
| Inventory | $648,000 | — | — | — | — |
| Total assets | $113.6M | $75.5M | $75.2M | $74.5M | $119.8M |
| Total liabilities | $71.8M | $62.4M | $58.5M | $8.1M | $7.2M |
| Shareholders' equity | $41.8M | $13.1M | $16.8M | $66.3M | $112.6M |
Source: SEC EDGAR filings · CIK 0001408443 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.